List of Excipients in Branded Drug LENALIDOMIDE

« Back to Dashboard

Generic Drugs Containing LENALIDOMIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	lenalidomide	0378-1935	AMMONIA
Mylan Pharmaceuticals Inc	lenalidomide	0378-1935	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	lenalidomide	0378-1935	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	lenalidomide	0378-1935	FD&C BLUE NO. 2
Mylan Pharmaceuticals Inc	lenalidomide	0378-1935	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in LENALIDOMIDE?

# Of NDCs	Excipient
10	AMMONIA
18	ANHYDROUS LACTOSE
18	CELLULOSE, MICROCRYSTALLINE
21	CROSCARMELLOSE SODIUM
3	FD&C BLUE NO. 1

Lenalidomide Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Lenalidomide is a mature, high-value oral oncology product with a relatively simple reference formulation but demanding manufacturing requirements. The commercial opportunity is concentrated in generic and differentiated oral solid-dose products, excipient substitution, capsule technology, low-dose content uniformity, supply security, and lifecycle formulations. The strongest strategies target excipients that improve blend uniformity, dissolution, stability, capsule performance, and regulatory differentiation without changing bioequivalence risk.

What is the current lenalidomide formulation?

Revlimid is an immediate-release hard gelatin capsule containing lenalidomide. The approved strengths are 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. The labeled inactive ingredients are anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The capsule shell contains gelatin and titanium dioxide, with printing ink containing black iron oxide and other permitted components depending on strength and market presentation (Bristol Myers Squibb, 2024).

Component	Function in the reference product	Strategic relevance
Anhydrous lactose	Diluent and bulk carrier	Supports capsule fill weight and powder processability
Microcrystalline cellulose	Diluent, dry binder, compaction aid	Supports flow, compressibility, and blend structure
Croscarmellose sodium	Superdisintegrant	Promotes rapid capsule plug dispersion and drug release
Magnesium stearate	Lubricant	Controls tooling and encapsulation friction
Gelatin	Hard capsule shell	Creates animal-origin and vegetarian-formulation considerations
Titanium dioxide	Opacifier and colorant	Subject to regional regulatory scrutiny
Black printing ink	Product identification	Supports strength differentiation and traceability

The formulation is commercially efficient because it uses common, established excipients. Its main technical challenge is the low drug load in the lower strengths. A 2.5 mg capsule can contain a small quantity of active pharmaceutical ingredient relative to the total excipient mass, increasing the risk of segregation, potency variability, and content-uniformity failures.

Why does lenalidomide create an excipient opportunity?

Lenalidomide has several characteristics that make excipient selection commercially relevant:

1. It is a potent oncology compound requiring controlled handling.
2. The product is supplied in multiple low-dose and high-dose strengths.
3. The reference product uses a conventional immediate-release capsule.
4. Generic products must demonstrate pharmaceutical equivalence and bioequivalence while managing hazardous-drug manufacturing controls.
5. The molecule has broad use in multiple myeloma, myelodysplastic syndromes associated with deletion 5q, and mantle cell lymphoma in certain jurisdictions and clinical settings (National Cancer Institute, 2024).

The opportunity is not primarily to replace one inexpensive excipient with another. It is to design a robust platform that can support six strengths, minimize manufacturing losses, reduce operator exposure, and maintain dissolution and content uniformity across commercial batches.

What excipient strategy best supports generic lenalidomide?

A conventional immediate-release powder-fill capsule remains the lowest-risk strategy for an ANDA or equivalent generic filing. The formulation should preserve the reference product’s key performance attributes while allowing controlled excipient substitution.

Recommended formulation architecture

A practical platform uses:

• A high-purity, narrow-particle-size lenalidomide API
• Anhydrous lactose or another rapidly dissolving diluent
• Microcrystalline cellulose for bulk and flow control
• Croscarmellose sodium for rapid disintegration
• Magnesium stearate at the lowest validated concentration
• Gelatin or hypromellose capsules, depending on regulatory and market objectives

The central development issue is blend uniformity. Geometric dilution, ordered mixing, carrier-based premixes, and validated low-shear blending can reduce segregation. The manufacturer should evaluate blend sampling by a statistically justified plan rather than relying only on final capsule testing.

Excipient selection priorities

Development objective	Preferred excipient approach	Main risk
Low-dose uniformity	Use a co-processed diluent or engineered carrier with controlled particle size	Segregation during transfer or capsule filling
Rapid dissolution	Retain a superdisintegrant and use a soluble diluent	Excessive lubricant or hydrophobic coating
Improved flow	Use spray-dried lactose, silicified microcrystalline cellulose, or a co-processed platform	Changed dissolution or capsule-fill density
Vegetarian product	Replace gelatin with hypromellose or pullulan shell	Shell brittleness, moisture sensitivity, or altered machine performance
Reduced titanium dioxide exposure	Use opaque HPMC shell with alternative color system	Product identification and regional colorant requirements
Reduced dust generation	Use granulated or engineered excipients	Higher process complexity and possible dissolution changes
Supply resilience	Qualify dual suppliers for each critical excipient	Comparability and change-control burden

Which excipients are most commercially attractive?

Co-processed excipients

Co-processed excipients can combine flow, compressibility, and disintegration properties in one material. Examples include silicified microcrystalline cellulose and spray-dried lactose systems. Their value is greatest in low-dose capsules where a more uniform carrier can reduce active segregation.

The regulatory advantage is practical rather than automatic. A co-processed excipient does not create a new market position unless it improves manufacturing performance, supports a differentiated formulation, or enables a protected product claim. The sponsor must establish that the excipient does not alter dissolution or bioequivalence.

Hypromellose capsules

Hypromellose capsules offer a gelatin-free presentation for vegetarian, religious, and selected institutional markets. They can also reduce dependence on animal-derived materials. Their performance depends on shell moisture, storage conditions, machine settings, and compatibility with the powder blend.

For lenalidomide, a hypromellose shell is a credible commercial differentiator because the active is already available as a standard hard capsule. The opportunity is strongest where procurement groups or national regulatory agencies favor non-animal dosage forms.

Lactose alternatives

Lactose is a low-cost and well-established diluent. Replacing it with mannitol, dicalcium phosphate, starch, or a co-processed excipient can support lactose-free positioning, but the commercial benefit must justify higher formulation and regulatory risk.

Mannitol may improve mouthfeel and offer a lactose-free platform, although it can change density and dissolution. Dicalcium phosphate can improve flow but may create compatibility or dissolution concerns. Starch-based systems can alter moisture behavior and may require more complex process controls.

Lactose substitution is therefore best positioned as a targeted market strategy rather than a default formulation change.

Lubricant systems

Magnesium stearate is standard, inexpensive, and generally effective. Its use should be tightly controlled because excessive lubrication can reduce wettability and delay dissolution. Alternative lubricants such as sodium stearyl fumarate may support a more hydrophilic formulation, but the substitution requires comparative dissolution, stability, and process validation.

Disintegrants

Croscarmellose sodium is a logical reference excipient because it supports rapid dispersion without requiring a complex formulation. Crospovidone and sodium starch glycolate are possible alternatives. Crospovidone may be attractive where rapid wicking and low gelling risk are priorities. Sodium starch glycolate can provide strong swelling but may be more sensitive to formulation level and process conditions.

What formulation patents could protect a lenalidomide product?

A standard excipient substitution is unlikely to provide strong, durable patent protection by itself. Patentable subject matter is more likely to arise from a combination of formulation, process, performance, and clinical-use features.

Potential formulation claim areas

• A specific lenalidomide-to-excipient ratio
• A defined particle-size distribution
• A low-segregation powder premix
• A capsule-fill process that achieves a specified content-uniformity range
• A dissolution profile across multiple pH conditions
• A moisture-controlled package and formulation combination
• A gelatin-free capsule with defined shell composition
• A taste-masked liquid or multiparticulate formulation
• A modified-release or pulsatile-release dosage form
• A formulation that reduces occupational dust exposure
• A pediatric dosage form with a validated administration method

A patent based only on replacing lactose with mannitol may face obviousness and enablement challenges. A stronger portfolio would link the excipient system to a measurable technical effect, such as improved low-dose uniformity, reduced degradation, enhanced dissolution, or improved handling safety.

How strong is the lenalidomide patent estate?

The original lenalidomide compound and core use patents have largely matured or expired in the United States and other major markets. Commercial exclusivity has nevertheless been extended through later patents, regulatory protections, restricted generic entry arrangements, and product-specific litigation.

The key commercial distinction is between:

• Compound and core composition patents
• Method-of-use patents
• Formulation and dosage-regimen patents
• Risk-evaluation and distribution controls
• Settlement-based generic launch restrictions

Revlimid was developed and commercialized by Celgene, which was acquired by Bristol Myers Squibb in 2019. BMS reported agreements allowing limited generic lenalidomide entry before broader commercial availability, subject to settlement terms and applicable regulatory requirements (Bristol Myers Squibb, 2019; U.S. Securities and Exchange Commission, 2024).

A formulation company should not assume that the expiration of a core compound patent creates unrestricted launch access. Orange Book listings, Paragraph IV certifications, litigation outcomes, and settlement provisions can materially affect entry timing.

What is the Orange Book and FDA status of lenalidomide?

Revlimid is an FDA-approved prescription product listed in the Orange Book. Generic applicants must address listed patents through the applicable ANDA certification pathway, including Paragraph IV certifications where they seek approval before patent expiration. FDA approval does not by itself eliminate commercial restrictions created by patent settlements or distribution controls (U.S. Food and Drug Administration, 2024a).

Lenalidomide is associated with a controlled distribution program because of its teratogenic risk. The U.S. Risk Evaluation and Mitigation Strategy, historically known as Revlimid REMS or a related restricted-distribution framework, affects prescriber, pharmacy, patient, and supply-chain procedures. This increases operational complexity for generic manufacturers and makes distribution infrastructure part of the product strategy (U.S. Food and Drug Administration, 2024b).

When does lenalidomide lose exclusivity?

There is no single global loss-of-exclusivity date. The timing varies by jurisdiction, patent family, settlement agreement, pediatric extensions, regulatory exclusivity, and product-specific litigation.

Exclusivity factor	Commercial effect
Core compound patents	Establish the original market protection period
Method-of-use patents	Can delay approval or require carve-outs
Formulation patents	May affect specific dosage forms or presentations
Pediatric exclusivity	Can add six months to certain U.S. protections
Paragraph IV litigation	Can trigger a 30-month stay in appropriate circumstances
Settlement agreements	Can permit limited entry before broad generic launch
REMS or restricted distribution	Raises launch and compliance costs
Regional patent differences	Produce different entry dates by country

Generic applicants typically prioritize strengths and indications with the largest volume and lowest development complexity. Lower-volume strengths may follow later because each additional strength increases analytical, stability, packaging, and supply-chain costs.

Which companies are challenging lenalidomide exclusivity?

The generic market has included major multinational and regional manufacturers, with applicants pursuing approval through ANDA or comparable national procedures. Publicly reported participants have included Teva, Dr. Reddy's Laboratories, Natco Pharma, Cipla, Sun Pharma, Zydus, and other manufacturers depending on jurisdiction and product strength.

The competitive field is shaped by more than API access. Important barriers include:

• Ability to source high-quality lenalidomide API
• Experience with potent or hazardous compounds
• REMS or restricted-distribution compliance
• Patent litigation budget
• Commercial launch timing
• Capacity across all approved strengths
• Hospital and specialty-pharmacy contracting
• Ability to maintain supply during price erosion

A manufacturer with an approved formulation but weak distribution capability may not capture meaningful share.

What commercial opportunities exist for excipient suppliers?

High-value opportunity areas

Low-dose uniformity platforms

Excipient suppliers can develop engineered carriers for 2.5 mg and 5 mg capsules. The value proposition should focus on reduced segregation, consistent fill weight, and lower batch rejection risk.

Vegetarian and regional capsule systems

HPMC capsule shells can support differentiated products in markets with restrictions or preferences relating to gelatin. Suppliers can add value through moisture-control systems, optimized machine compatibility, and validated colorant packages.

Hazardous-drug handling

Excipient and process suppliers can offer low-dust grades, closed-transfer systems, and containment-compatible formulation platforms. The commercial buyer is often the generic manufacturer, contract development and manufacturing organization, or specialty-pharmacy supplier.

Dual-source supply

Lenalidomide manufacturers have an incentive to qualify alternative suppliers for lactose, microcrystalline cellulose, disintegrants, lubricants, and capsule shells. Suppliers with robust change-control packages, multiple manufacturing sites, and regulatory documentation can secure premium positions.

Pediatric or liquid formulations

A liquid, suspension, orally disintegrating, or multiparticulate product could create lifecycle value if clinical demand and regulatory requirements support it. The formulation must address solubility, palatability, dose accuracy, stability, and safe handling. Because lenalidomide is a potent teratogenic drug, patient and caregiver exposure controls are central to commercialization.

How does lenalidomide compare with competing oncology products?

Lenalidomide competes commercially with pomalidomide, thalidomide, bortezomib, carfilzomib, daratumumab, and newer multiple-myeloma regimens. Its excipient opportunity differs from injectable products because the manufacturing focus is oral solid-dose performance rather than parenteral stability.

Product	Main dosage form	Excipient opportunity
Lenalidomide	Immediate-release capsule	Low-dose uniformity, capsule shell, stability, generic platform
Pomalidomide	Capsule	Similar potent-compound controls and multi-strength strategy
Thalidomide	Capsule	Restricted distribution and capsule differentiation
Bortezomib	Injectable	Sterility, lyophilization, reconstitution excipients
Carfilzomib	Injectable	Parenteral formulation and stability systems
Daratumumab	Biologic, injectable or subcutaneous	Protein stabilization and delivery technology

Lenalidomide’s oral route supports broader manufacturing scalability than injectable competitors, but it also attracts more generic competition after patent barriers decline.

What generic launch risks exist for lenalidomide?

The principal risks are regulatory, legal, technical, and commercial.

Regulatory risk

Bioequivalence must be demonstrated with a formulation that may differ in excipient composition but remains pharmaceutically equivalent. Dissolution behavior must be controlled across strengths and relevant media. Changes in capsule shell or diluent can create unexpected variability.

Manufacturing risk

The active is potent, and containment failures can cause worker-safety incidents, cross-contamination, batch loss, or regulatory action. Low-dose products amplify blending and sampling risks.

Legal risk

Patent disputes may concern methods of treatment, dosing regimens, formulations, or use in specific patient populations. Settlement agreements can limit volume or timing even when regulatory approval is available.

Commercial risk

Post-entry price erosion may be rapid. A differentiated capsule shell or lactose-free presentation may protect a premium niche but will not necessarily support premium pricing across the entire market.

Supply risk

The product requires reliable API, excipient, capsule, packaging, and specialty-distribution capacity. A single-source strategy can undermine an otherwise competitive product.

What is the best commercial strategy for an excipient-led lenalidomide product?

The most credible strategy is a platform approach rather than a single-excipient claim:

1. Use a conventional immediate-release formulation as the regulatory baseline.
2. Optimize engineered excipients for low-dose blend uniformity.
3. Offer gelatin and HPMC capsule options.
4. Establish dual suppliers for critical excipients.
5. Validate low-dust processing and containment compatibility.
6. Generate comparative dissolution and stability data early.
7. Protect the formulation with composition, process, and performance claims where technically justified.
8. Target specialty-generic manufacturers and CDMOs preparing for post-settlement competition.
9. Develop separate market variants for lactose-free, vegetarian, and region-specific requirements.
10. Avoid unnecessary formulation novelty in the first regulatory filing.

Key Takeaways

• Lenalidomide is a high-value, immediate-release hard-capsule product with a conventional excipient system.
• The largest technical challenge is content uniformity in the 2.5 mg and 5 mg strengths.
• Engineered or co-processed excipients offer the clearest near-term value for generic manufacturers.
• HPMC capsules create a practical vegetarian and animal-origin-free differentiation strategy.
• Lactose substitution can support niche positioning but increases development and bioequivalence risk.
• Excipient patents are strongest when linked to measurable improvements in uniformity, dissolution, stability, or handling.
• Patent expiry does not establish a single global launch date because settlement agreements, method-of-use patents, and distribution controls vary by market.
• Manufacturing containment and restricted distribution are material barriers to entry.
• Excipient suppliers can capture value through formulation platforms, dual-source qualification, low-dust grades, capsule technologies, and regulatory support.
• The preferred development path is a conservative immediate-release platform with targeted differentiation rather than a high-risk novel delivery system.

FAQs

Can lenalidomide be formulated without lactose?

Yes. Mannitol, microcrystalline cellulose, dicalcium phosphate, starch-based excipients, and co-processed materials are potential alternatives. The substitute must preserve blend uniformity, dissolution, stability, and bioequivalence.

Are HPMC capsules suitable for lenalidomide?

HPMC capsules can be suitable if shell moisture, fill-machine compatibility, stability, and dissolution are validated. They support vegetarian and gelatin-free positioning.

Is lenalidomide a good candidate for an orally disintegrating tablet?

The concept is technically possible, but the commercial case is less certain than for a conventional capsule. Potency, taste, dose uniformity, dust control, and patient-handling precautions may offset convenience benefits.

Can an excipient supplier patent a lenalidomide formulation?

Yes, if the formulation contains patentable composition, process, or performance features. A simple substitution of one standard diluent for another is less likely to produce strong protection.

What is the highest-value excipient opportunity in lenalidomide?

The strongest opportunity is an engineered low-dose carrier system that improves content uniformity and reduces segregation across all capsule strengths while remaining compatible with immediate-release dissolution and generic regulatory requirements.

References

1. Bristol Myers Squibb. (2019). Bristol Myers Squibb completes acquisition of Celgene. https://news.bms.com

2. Bristol Myers Squibb. (2024). Revlimid (lenalidomide) capsules: U.S. prescribing information. https://packageinserts.bms.com

3. National Cancer Institute. (2024). Lenalidomide. https://www.cancer.gov

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2024b). Risk evaluation and mitigation strategies. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems

6. U.S. Securities and Exchange Commission. (2024). Bristol Myers Squibb Company annual report. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000014272